A by-product from Utah-based Intermountain Well being has raised $10 million to deliver longitudinal organic and scientific knowledge to biopharmaceutical corporations. 

End result Bio says it maintains unique rights to a bodily library and cloud-based knowledge lake overlaying over 40 years of de-identified affected person digital well being information and biospecimen knowledge. This intensive knowledge lake can permit biopharmaceutical corporations to realize insights important to facilitating diagnostic and healing building. 

The corporate notes that it will probably take over a decade and billions of bucks to procure regulatory popularity of therapies or diagnostic gear. The issue begins with having access to longitudinal organic and scientific affected person knowledge, which will take lifestyles sciences and biotech corporations months to assemble and procedure.   

With a frequently rising library of over 5 million de-identified affected person samples and scientific knowledge spanning a long time, End result Bio can be offering fast get admission to to retrospective affected person knowledge and quicker get admission to to 1000’s of potential sufferers for research.

The $10 million funding is from Merck International Well being Innovation Fund and Amgen Ventures. 

“With make stronger from our buyers, End result Bio is elevating the bar for healthcare innovation,” stated Lincoln Nadauld, M.D., Ph.D., president and CEO of End result Bio, in a observation. He was once in the past vice chairman, leader of precision well being & lecturers at Intermountain. 

“On most sensible of our present longitudinal affected person knowledge, we’re including over 300,000 biospecimens to our knowledge lake each and every 12 months,” Nadauld added. “On account of this, we be able to temporarily determine distinctive affected person cohorts from our huge knowledge lake that may accelerate important analysis, resulting in novel discoveries..”

Along with rushing up affected person recruitment, the brand new corporate stated the platform gives fast question functions throughout genomic, organic, scientific, and claims knowledge, which has already supported analysis on the whole thing from population-wide genetic research to drug discovery.

“End result’s Intelligence Platform supplies collaborators with get admission to to uniquely wealthy de-identified scientific datasets,” stated David M. Rubin, Ph.D., managing director at Merck International Well being Innovation Fund (GHIF), in a observation. “GHIF appears ahead to operating with the proficient and skilled End result control staff to harness the facility of precision medication to strengthen results for sufferers.”